secwatch.observer — SEC 8-K summary
======================================

Issuer:     AMICUS THERAPEUTICS, INC. (—)
CIK:        0001178879
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0001104659-24-059089
Event type: earnings
Sentiment:  positive
Materiality: 0.78
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amicus Q1 revenue $110.4M (+28% YoY); raises Galafold growth guidance to 13-17%
-------------------------------------------------------------------------------

- Total revenue $110.4M, up 28% YoY; Galafold net sales $99.4M (+15% YoY).
- Pombiliti+Opfolda net sales $11.0M, up 30% from Q4 2023; over 155 patients on/commercial treatment.
- GAAP net loss $48.4M ($0.16/sh); non-GAAP net loss $4.6M ($0.02/sh), improved from $16.8M loss in Q1 2023.
- Raises full-year Galafold revenue growth guidance to 13-17% (from 11-16%); total revenue growth guided 25-30%.
- Cash and securities $239.6M; reiterates full-year non-GAAP profitability projected in 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1178879/000110465924059089/0001104659-24-059089-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1178879/000110465924059089/tm2413954d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-059089

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer